Midland, Mich. - February 27, 2007 -- Dow Global Technologies Inc. today announced that Serum Institute of India Limited has entered into a commercial license agreement for Pfenex Expression Technology™, a Pseudomonas-based technology from DowpharmaSM. The first product under the agreement is a confidential proprietary protein for which a high-yield production strain has already been developed by Dowpharma. Dowpharma will transfer the production strain to Serum Institute of India with full support for its regulatory filing.
